Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters










Database
Language
Publication year range
1.
Int J Parasitol Drugs Drug Resist ; 7(1): 34-41, 2017 04.
Article in English | MEDLINE | ID: mdl-28040568

ABSTRACT

Trypanosomes are blood protozoan parasites that are capable of producing illness in the vertebrate host. Within Australia, several native Trypanosoma species have been described infecting wildlife. However, only Trypanosoma copemani has been associated with pathological lesions in wildlife hosts and more recently has been associated with the drastic decline of the critically endangered woylie (Bettongia penicillata). The impact that some trypanosomes have on the health of the vertebrate host has led to the development of numerous drug compounds that could inhibit the growth or kill the parasite. This study investigated and compared the in vitro susceptibility of two strains of T. copemani (G1 and G2) and one strain of Trypanosoma cruzi (10R26) against drugs that are known to show trypanocidal activity (benznidazole, posaconazole, miltefosine and melarsoprol) and against four lead compounds, two fenarimols and two pyridine derivatives (EPL-BS1937, EPL-BS2391, EPL-BS0967, and EPL-BS1246), that have been developed primarily against T.cruzi. The in vitro cytotoxicity of all drugs against L6 rat myoblast cells was also assessed. Results showed that both strains of T. copemani were more susceptible to all drugs and lead compounds than T. cruzi, with all IC50 values in the low and sub-µM range for both species. Melarsoprol and miltefosine exhibited the highest drug activity against both T. copemani and T. cruzi, but they also showed the highest toxicity in L6 cells. Interestingly, both fenarimol and pyridine derivative compounds were more active against T. copemani and T. cruzi than the reference drugs benznidazole and posaconazole. T. copemani strains exhibited differences in susceptibility to all drugs demonstrating once again considerable differences in their biological behaviour.


Subject(s)
Animals, Wild/parasitology , Trypanocidal Agents/pharmacology , Trypanosoma cruzi/drug effects , Trypanosoma/drug effects , Animals , Australia , Cell Line , Drug Discovery , High-Throughput Screening Assays , Inhibitory Concentration 50 , Melarsoprol/pharmacology , Melarsoprol/toxicity , Nitroimidazoles/pharmacology , Phosphorylcholine/analogs & derivatives , Phosphorylcholine/pharmacology , Phosphorylcholine/toxicity , Potoroidae/parasitology , Pyrimidines/pharmacology , Triazoles/pharmacology , Trypanosoma/isolation & purification , Trypanosoma cruzi/isolation & purification
2.
Cancer Res ; 59(5): 1041-8, 1999 Mar 01.
Article in English | MEDLINE | ID: mdl-10070961

ABSTRACT

Recent data have renewed the interest for arsenic-containing compounds as anticancer agents. In particular, arsenic trioxide (As2O3) has been demonstrated to be an effective drug in the treatment of acute promyelocytic leukemia by inducing programmed cell death in leukemic cells both in vitro and in vivo. This prompted us to study the in vitro effects of As2O3 and of another arsenical derivative, the organic compound melarsoprol, on human myeloma cells and on the plasma cell differentiation of normal B cells. At pharmacological concentrations (10(-8) to 10(-6) mol/L), As2O3 and melarsoprol caused a dose- and time-dependent inhibition of survival and growth in myeloma cell lines that was, in some, similar to that of acute promyelocytic leukemia cells. Both arsenical compounds induced plasma cell apoptosis, as assessed by 4',6-diamidino-2-phenylindole staining, detection of phosphatidylserine at the cell surface using annexin V, and by the terminal deoxynucleotidyl transferase-mediated nick end labeling assay. As2O3 and melarsoprol also inhibited viability and growth and induced apoptosis in plasma-cell enriched preparations from the bone marrow or blood of myeloma patients. In nonseparated bone marrow samples, both arsenical compounds triggered death in myeloma cells while sparing most myeloid cells, as demonstrated by double staining with annexin V and CD38 or CD15 antibodies. In primary myeloma cells as in cell lines, interleukin 6 did not prevent arsenic-induced cell death or growth inhibition, and no synergistic effect was observed with IFN-alpha. In contrast to As2O3, melarsoprol only slightly reduced the plasma cell differentiation of normal B cells induced by pokeweed mitogen. Both pokeweed mitogen-induced normal plasma cells and malignant plasma cells showed a normal nuclear distribution of PML protein, which was disrupted by As2O3 but not by melarsoprol, suggesting that the two arsenical derivatives acted by different mechanisms. These results point to the use of arsenical derivatives as investigational drugs in the treatment of multiple myeloma.


Subject(s)
Antineoplastic Agents/toxicity , Apoptosis/drug effects , Arsenic Poisoning , Arsenicals , Melarsoprol/toxicity , Multiple Myeloma/immunology , Oxides/toxicity , Plasma Cells/drug effects , Arsenic Trioxide , Cell Division/drug effects , Cell Line , Cell Survival/drug effects , Flow Cytometry , Fluorescent Antibody Technique, Indirect , Humans , Kinetics , Lymphocyte Activation , Multiple Myeloma/blood , Neoplasm Proteins/analysis , Neoplasm Proteins/biosynthesis , Nuclear Proteins/analysis , Plasma Cells/cytology , Plasma Cells/pathology , Promyelocytic Leukemia Protein , Transcription Factors/analysis , Transcription Factors/biosynthesis , Tumor Suppressor Proteins
3.
Blood ; 90(2): 562-70, 1997 Jul 15.
Article in English | MEDLINE | ID: mdl-9226155

ABSTRACT

Inorganic arsenic trioxide (As2O3) was recently shown to induce apoptosis in NB4 promyelocytic leukemic cells. We have investigated the effects of the organic arsenical, melarsoprol (a drug used for treatment of trypanosomiasis), upon induction of apoptosis in cell lines representative of chronic B-cell lymphoproliferative disorders. An Epstein-Barr virus (EBV)-transformed B-prolymphocytic cell line (JVM-2), an EBV-transformed B-cell chronic lymphocytic leukemia (B-CLL) cell line (I83CLL), and one non-EBV-transformed B-CLL cell line (WSU-CLL) were used as targets. Dose-response experiments with melarsoprol (10(-7) to 10(-9) mol/L) were performed over 96 hours. Unexpectedly, we found that melarsoprol caused a dose- and time-dependent inhibition of survival and growth in all three cell lines. In contrast, As2O3 at similar concentrations had no effect on either viability or growth. After 24 hours, all three cell lines treated with melarsoprol (10(-7) mol/L) exhibited morphologic characteristics of apoptosis. We also observed prominent concentration-dependent downregulation of bcl-2 mRNA after 24 hours of exposure to melarsoprol in WSU-CLL, I83CLL, and JVM-2 cells. Decrease of bcl-2 protein expression was also observed in all three cell lines, whereas As2O3 had no effect on this parameter. We conclude that melarsoprol may inhibit the growth of lymphoid leukemic cell by promoting programmed cell death. Results of these studies suggest that melarsoprol shows promising therapeutic activity in these diseases, and a study to evaluate clinical effects of this drug has been initiated.


Subject(s)
Antineoplastic Agents/toxicity , Arsenic Poisoning , Arsenicals , Melarsoprol/toxicity , Oxides/toxicity , Apoptosis/drug effects , Arsenic Trioxide , Cell Division/drug effects , Cell Line, Transformed , Cell Survival/drug effects , DNA Damage , DNA Fragmentation , Drug Screening Assays, Antitumor , Herpesvirus 4, Human , Humans , Kinetics , Leukemia, Lymphocytic, Chronic, B-Cell , Proto-Oncogene Proteins c-bcl-2/biosynthesis , RNA, Messenger/biosynthesis , Time Factors , Transcription, Genetic/drug effects , Tumor Cells, Cultured
4.
Vet Parasitol ; 62(1-2): 43-50, 1996 Mar.
Article in English | MEDLINE | ID: mdl-8638392

ABSTRACT

A study was conducted in vitro to assess the ability of calcium antagonists to reverse trypanocidal resistance in Trypanosoma evansi. Susceptibility patterns of sensitive and resistant parasites were evaluated against calcium antagonists of several chemical classes (verapamil, cyproheptidine, desipramine and chlopromazine), alone and in combination with suramin, diminazene aceturate or melarsen oxide cyteamine. The putative resistance modulators were intrinsically antitrypanosomal, but were unable to reverse resistance to any of the trypanocides tested. It was thus concluded that resistance to these trypanocides in T. evansi may differ from drug resistance mechanisms occurring in cancer cells, malaria or in South American trypanosomosis, where calcium antagonists have successfully reversed resistance.


Subject(s)
Calcium Channel Blockers/toxicity , Drug Resistance, Multiple , Trypanocidal Agents/toxicity , Trypanosoma/drug effects , Animals , Chlorpromazine/toxicity , Cyproheptadine/toxicity , Desipramine/toxicity , Diminazene/analogs & derivatives , Diminazene/toxicity , Dose-Response Relationship, Drug , Drug Interactions , Melarsoprol/toxicity , Suramin/toxicity , Trypanosoma/growth & development , Verapamil/toxicity
5.
Article in English | MEDLINE | ID: mdl-7693393

ABSTRACT

1. Trypanosoma brucei brucei-infected mouse models treated with a new antibiotic, reuterin, showed reduction of the levels of parasitemia and prolonged survival of the mice. 2. Cures of the parasitemia were observed in groups of mice treated with combinations of reuterin and suramin or melarsoprol. 3. Reuterin administered in combination with bleomycin or DL-alpha-difluoromethylornithine showed temporary remission of the parasitemia in groups of mice.


Subject(s)
Anti-Bacterial Agents/therapeutic use , Trypanosomiasis, African/drug therapy , Aldehydes , Animals , Anti-Bacterial Agents/administration & dosage , Anti-Bacterial Agents/toxicity , Bleomycin/administration & dosage , Bleomycin/therapeutic use , Bleomycin/toxicity , Drug Therapy, Combination , Eflornithine/administration & dosage , Eflornithine/therapeutic use , Eflornithine/toxicity , Female , Glyceraldehyde/analogs & derivatives , Lethal Dose 50 , Melarsoprol/administration & dosage , Melarsoprol/therapeutic use , Melarsoprol/toxicity , Mice , Propane , Suramin/administration & dosage , Suramin/therapeutic use , Suramin/toxicity , Trypanosomiasis, African/parasitology
SELECTION OF CITATIONS
SEARCH DETAIL
...